Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer

Rodolfo Montironi, Roberta Mazzucchelli, Francesca Barbisan, Daniela Stramazzotti, Alfredo Santinelli, Antonio Lòpez Beltran, Liang Cheng, Francesco Montorsi, Marina Scarpelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objectives: To analyze the expression of endothelin-1 (ET-1), endothelin-A receptor (ET-A-R), and endothelin-B receptor (ET-B-R) in incidental prostate cancer in cystoprostatectomies (CyPs), clinically detected hormonally untreated and hormonally treated prostate cancer in radical prostatectomies (RPs), and hormone-independent prostate cancer in transurethral resections of the prostate (TURPs). High-grade prostatic intraepithelial neoplasia (HGPIN) was also investigated. Methods: Nineteen CyPs and 44 RPs (25 untreated, 19 treated) with pT2a Gleason score 6 cancer and HGPIN were examined. The study included 9 TURPs with hormone-independent cancer and 8 normal cases from CyPs without prostate cancer and HGPIN. ET-1, ET-A-R, ET-B-R, and the proliferation marker Ki67 were investigated immunohistochemically. Results: The mean proportion of prostate cancer cells with strong ET-1, ET-A-R, and ET-B-R expression in CyPs was lower (18.5%, 28.0%, and 14.7%, respectively) than in the untreated group (40.7%, 39.7%, and 25.1%) and higher than in treated group (5.0%, 13.9%, and 11.3%). The highest values were in the hormone-independent cancer group (53.9%, 48.9%, 33.3%). The trend in the proportion of HGPIN cells overexpressing ET-1, ET-A-R, and ET-B-R was similar to that in the cancer groups. The values in HGPIN lesions were always slightly greater than those in the cancers. Ki67 expression in HGPIN and prostate cancer in CyPs was lower than in RPs and TURPs. Conclusions: Our study showed for the first time that ET-1, ET-A-R, and ET-B-R expression is not limited to the late prostate cancer phases. It is also seen in HGPIN as well as in prostate cancers considered to be clinically insignificant, such as those seen in CyP specimens. Although the series of cases in each group was small, our data may have clinical significance.

Original languageEnglish
Pages (from-to)1682-1690
Number of pages9
JournalEuropean Urology
Volume52
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Prostatic Intraepithelial Neoplasia
Endothelin B Receptors
Endothelins
Endothelin-1
Prostatic Neoplasms
Endothelin A Receptors
Transurethral Resection of Prostate
Prostatectomy
Hormones
Neoplasms
Neoplasm Grading

Keywords

  • Cystoprostatectomy
  • Endothelin-1
  • Endothelin-A receptor
  • Endothelin-B receptor
  • High-grade prostatic intraepithelial neoplasia
  • Insignificant cancer
  • Prostate cancer
  • Significant cancer

ASJC Scopus subject areas

  • Urology

Cite this

Montironi, R., Mazzucchelli, R., Barbisan, F., Stramazzotti, D., Santinelli, A., Lòpez Beltran, A., ... Scarpelli, M. (2007). Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. European Urology, 52(6), 1682-1690. https://doi.org/10.1016/j.eururo.2007.02.024

Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. / Montironi, Rodolfo; Mazzucchelli, Roberta; Barbisan, Francesca; Stramazzotti, Daniela; Santinelli, Alfredo; Lòpez Beltran, Antonio; Cheng, Liang; Montorsi, Francesco; Scarpelli, Marina.

In: European Urology, Vol. 52, No. 6, 12.2007, p. 1682-1690.

Research output: Contribution to journalArticle

Montironi, R, Mazzucchelli, R, Barbisan, F, Stramazzotti, D, Santinelli, A, Lòpez Beltran, A, Cheng, L, Montorsi, F & Scarpelli, M 2007, 'Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer', European Urology, vol. 52, no. 6, pp. 1682-1690. https://doi.org/10.1016/j.eururo.2007.02.024
Montironi, Rodolfo ; Mazzucchelli, Roberta ; Barbisan, Francesca ; Stramazzotti, Daniela ; Santinelli, Alfredo ; Lòpez Beltran, Antonio ; Cheng, Liang ; Montorsi, Francesco ; Scarpelli, Marina. / Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. In: European Urology. 2007 ; Vol. 52, No. 6. pp. 1682-1690.
@article{b8e2fcf4d5cd4ef78b8a3c5ffe9bbe08,
title = "Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer",
abstract = "Objectives: To analyze the expression of endothelin-1 (ET-1), endothelin-A receptor (ET-A-R), and endothelin-B receptor (ET-B-R) in incidental prostate cancer in cystoprostatectomies (CyPs), clinically detected hormonally untreated and hormonally treated prostate cancer in radical prostatectomies (RPs), and hormone-independent prostate cancer in transurethral resections of the prostate (TURPs). High-grade prostatic intraepithelial neoplasia (HGPIN) was also investigated. Methods: Nineteen CyPs and 44 RPs (25 untreated, 19 treated) with pT2a Gleason score 6 cancer and HGPIN were examined. The study included 9 TURPs with hormone-independent cancer and 8 normal cases from CyPs without prostate cancer and HGPIN. ET-1, ET-A-R, ET-B-R, and the proliferation marker Ki67 were investigated immunohistochemically. Results: The mean proportion of prostate cancer cells with strong ET-1, ET-A-R, and ET-B-R expression in CyPs was lower (18.5{\%}, 28.0{\%}, and 14.7{\%}, respectively) than in the untreated group (40.7{\%}, 39.7{\%}, and 25.1{\%}) and higher than in treated group (5.0{\%}, 13.9{\%}, and 11.3{\%}). The highest values were in the hormone-independent cancer group (53.9{\%}, 48.9{\%}, 33.3{\%}). The trend in the proportion of HGPIN cells overexpressing ET-1, ET-A-R, and ET-B-R was similar to that in the cancer groups. The values in HGPIN lesions were always slightly greater than those in the cancers. Ki67 expression in HGPIN and prostate cancer in CyPs was lower than in RPs and TURPs. Conclusions: Our study showed for the first time that ET-1, ET-A-R, and ET-B-R expression is not limited to the late prostate cancer phases. It is also seen in HGPIN as well as in prostate cancers considered to be clinically insignificant, such as those seen in CyP specimens. Although the series of cases in each group was small, our data may have clinical significance.",
keywords = "Cystoprostatectomy, Endothelin-1, Endothelin-A receptor, Endothelin-B receptor, High-grade prostatic intraepithelial neoplasia, Insignificant cancer, Prostate cancer, Significant cancer",
author = "Rodolfo Montironi and Roberta Mazzucchelli and Francesca Barbisan and Daniela Stramazzotti and Alfredo Santinelli and {L{\`o}pez Beltran}, Antonio and Liang Cheng and Francesco Montorsi and Marina Scarpelli",
year = "2007",
month = "12",
doi = "10.1016/j.eururo.2007.02.024",
language = "English",
volume = "52",
pages = "1682--1690",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer

AU - Montironi, Rodolfo

AU - Mazzucchelli, Roberta

AU - Barbisan, Francesca

AU - Stramazzotti, Daniela

AU - Santinelli, Alfredo

AU - Lòpez Beltran, Antonio

AU - Cheng, Liang

AU - Montorsi, Francesco

AU - Scarpelli, Marina

PY - 2007/12

Y1 - 2007/12

N2 - Objectives: To analyze the expression of endothelin-1 (ET-1), endothelin-A receptor (ET-A-R), and endothelin-B receptor (ET-B-R) in incidental prostate cancer in cystoprostatectomies (CyPs), clinically detected hormonally untreated and hormonally treated prostate cancer in radical prostatectomies (RPs), and hormone-independent prostate cancer in transurethral resections of the prostate (TURPs). High-grade prostatic intraepithelial neoplasia (HGPIN) was also investigated. Methods: Nineteen CyPs and 44 RPs (25 untreated, 19 treated) with pT2a Gleason score 6 cancer and HGPIN were examined. The study included 9 TURPs with hormone-independent cancer and 8 normal cases from CyPs without prostate cancer and HGPIN. ET-1, ET-A-R, ET-B-R, and the proliferation marker Ki67 were investigated immunohistochemically. Results: The mean proportion of prostate cancer cells with strong ET-1, ET-A-R, and ET-B-R expression in CyPs was lower (18.5%, 28.0%, and 14.7%, respectively) than in the untreated group (40.7%, 39.7%, and 25.1%) and higher than in treated group (5.0%, 13.9%, and 11.3%). The highest values were in the hormone-independent cancer group (53.9%, 48.9%, 33.3%). The trend in the proportion of HGPIN cells overexpressing ET-1, ET-A-R, and ET-B-R was similar to that in the cancer groups. The values in HGPIN lesions were always slightly greater than those in the cancers. Ki67 expression in HGPIN and prostate cancer in CyPs was lower than in RPs and TURPs. Conclusions: Our study showed for the first time that ET-1, ET-A-R, and ET-B-R expression is not limited to the late prostate cancer phases. It is also seen in HGPIN as well as in prostate cancers considered to be clinically insignificant, such as those seen in CyP specimens. Although the series of cases in each group was small, our data may have clinical significance.

AB - Objectives: To analyze the expression of endothelin-1 (ET-1), endothelin-A receptor (ET-A-R), and endothelin-B receptor (ET-B-R) in incidental prostate cancer in cystoprostatectomies (CyPs), clinically detected hormonally untreated and hormonally treated prostate cancer in radical prostatectomies (RPs), and hormone-independent prostate cancer in transurethral resections of the prostate (TURPs). High-grade prostatic intraepithelial neoplasia (HGPIN) was also investigated. Methods: Nineteen CyPs and 44 RPs (25 untreated, 19 treated) with pT2a Gleason score 6 cancer and HGPIN were examined. The study included 9 TURPs with hormone-independent cancer and 8 normal cases from CyPs without prostate cancer and HGPIN. ET-1, ET-A-R, ET-B-R, and the proliferation marker Ki67 were investigated immunohistochemically. Results: The mean proportion of prostate cancer cells with strong ET-1, ET-A-R, and ET-B-R expression in CyPs was lower (18.5%, 28.0%, and 14.7%, respectively) than in the untreated group (40.7%, 39.7%, and 25.1%) and higher than in treated group (5.0%, 13.9%, and 11.3%). The highest values were in the hormone-independent cancer group (53.9%, 48.9%, 33.3%). The trend in the proportion of HGPIN cells overexpressing ET-1, ET-A-R, and ET-B-R was similar to that in the cancer groups. The values in HGPIN lesions were always slightly greater than those in the cancers. Ki67 expression in HGPIN and prostate cancer in CyPs was lower than in RPs and TURPs. Conclusions: Our study showed for the first time that ET-1, ET-A-R, and ET-B-R expression is not limited to the late prostate cancer phases. It is also seen in HGPIN as well as in prostate cancers considered to be clinically insignificant, such as those seen in CyP specimens. Although the series of cases in each group was small, our data may have clinical significance.

KW - Cystoprostatectomy

KW - Endothelin-1

KW - Endothelin-A receptor

KW - Endothelin-B receptor

KW - High-grade prostatic intraepithelial neoplasia

KW - Insignificant cancer

KW - Prostate cancer

KW - Significant cancer

UR - http://www.scopus.com/inward/record.url?scp=35348833842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348833842&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2007.02.024

DO - 10.1016/j.eururo.2007.02.024

M3 - Article

VL - 52

SP - 1682

EP - 1690

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -